Existing and investigational combination drug therapy for high-density lipoprotein cholesterol (Q40617312)

22 September 2017

Existing and investigational combination drug therapy for high-density lipoprotein cholesterol (English)

1 reference

22 September 2017

Harold Bays

1

1 reference

PubMed ID

12467938

22 September 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

American Journal of Cardiology

22 September 2017

1 reference

22 September 2017

90

1 reference

22 September 2017

10B

1 reference

22 September 2017

30K-43K

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

The benefits of niacin in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Drug interactions of lipid-altering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Mechanistic studies on metabolic interactions between gemfibrozil and statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Regulation of lipid and lipoprotein metabolism by PPAR activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Pharmacotherapy of disorders of plasma lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Effects of high-density lipoprotein(2) on cholesterol transport and acyl-coenzyme A:cholesterol acyltransferase activity in P388D1 macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902971-5

10.1016/S0002-9149(02)02971-5

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

12467938